Adipokines: Emerging therapeutic targets

Current Opinion in Investigational Drugs

Volumn 10, Issue 10, 2009, Pages 1061-1068

  Kos, K ^a,b   Wilding, J P H ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Adipokine; Chemerin; Leptin; Resistin; SPARC; Vaspin; Visfatin; White adipose tissue

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; COLLAGEN TYPE 6; COLLAGEN TYPE 6 ALPHA3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEONECTIN; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

ADIPOCYTE; ADIPOSE TISSUE; BODY WEIGHT; DRUG TARGETING; HORMONE DETERMINATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; WHITE ADIPOSE TISSUE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DRUG DELIVERY SYSTEMS; HUMANS; LEPTIN;

EID: 70349753310     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Unger RH: Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab (2003) 14(9):398-403. (Pubitemid 37392211)
2. Trayhurn P, Wood IS: Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr (2004) 92(3):347-355. (Pubitemid 40277057)
3. Rajala MW, Scherer PE: The adipocyte - At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology (2003) 144(9):3765-3773. (Pubitemid 37088727)
4. Wang P, Mariman E, Renes J, Keijer J: The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol (2008) 216(1):3-13. (Pubitemid 351813090)
5. Arner P: Resistin: Yet another adipokine tells us that men are not mice. Diabetologia (2005) 48(11):2203-2205.
6. Trayhurn P, Bing C, Wood IS: Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr (2006) 136(7 Suppl):1935S-1939S. •• Provides a comprehensive review of the biology of human adipose tissue.
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796-1808. (Pubitemid 38063703)
8. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA et al: Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med (1995) 1(11):1155-1161.
9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425-432. (Pubitemid 24365442)
10. Farooqi IS, O'Rahilly S: Leptin: A pivotal regulator of human energy homeostasis. Am J Clin Nutr (2009) 89(3):980S-984S.
11. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, Depaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M: The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab (2009) 94(4):1137-1144.
12. Schwartz MW, Morton GJ: Obesity: Keeping hunger at bay. Nature (2002) 418(6898):595-597.
13. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M: Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA (1999) 282(16): 1568-1575. (Pubitemid 29504050)
14. Iliopoulos D, Malizos KN, Tsezou A: Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: Possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis (2007) 66(12):1616-1621. (Pubitemid 350205450)
15. Lago R, Gómez R, Lago F, Gómez-Reino J, Gualillo O: Leptin beyond body weight regulation - Current concepts concerning its role in immune function and inflammation. Cell Immunol (2008) 252(1-2):139-145. •• Reviews the peripheral action of leptin, with particular emphasis of the role of leptin in inflammation.
16. Matarese G, Procaccini C, De Rosa V: The intricate interface between immune and metabolic regulation: A role for leptin in the pathogenesis of multiple sclerosis? J Leukoc Biol (2008) 84(4):893-899.
17. Flier JS: Obesity wars: Molecular progress confronts an expanding epidemic. Cell (2004) 116(2):337-350.
18. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res (2009) 11(3):R36.
19. Haraoui B, Bykerk V: Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag (2007) 3(1):99-105.
20. Dube MG, Torto R, Kalra SP: Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice. Peptides (2008) 29(4):593-598.
21. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, Rahmouni K: Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension (2009) 53(2):375-380.
22. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG: Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes (2005) 54(7):2012-2018. (Pubitemid 40911263)
23. Pischon T, Nöthlings U, Boeing H: Obesity and cancer. Proc Nutr Soc (2008) 67(2):128-145.
24. Scheuner D, Vander Mierde D, Song B, Flamez D, Creemers JW, Tsukamoto K, Ribick M, Schuit FC, Kaufman RJ: Control of mRNA translation preserves endoplasmic reticulum function in β cells and maintains glucose homeostasis. Nat Med (2005) 11(7): 757-764. (Pubitemid 41021208)
25. Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 8(7): 519-529. (Pubitemid 46985379)
26. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D: Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 135(1):61-73.
27. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr, Ozcan U: Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab (2009) 9(1):35-51.
28. Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol (2002) 440(2-3):213-221.
29. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem (2003) 278(11):9073-9085. (Pubitemid 36800387)
30. Dong F, Ren J: Adiponectin improves cardiomyocyte contractile function in db/db diabetic obese mice. Obesity (2009) 17(2): 262-268.
31. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam F, Ouchi N, Walsh K: Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol (2007) 42(6):1065-1074. (Pubitemid 46829193)
32. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O: A new player in cartilage homeostasis: Adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage (2008) 16(9):1101-1109.
33. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H: Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol (2006) 33(8):1545-1552. (Pubitemid 44168825)
34. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S: Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes (2001) 50(10):2199-2202. (Pubitemid 33641901)
35. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP et al: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA (2004) 101(16):6062-6067. (Pubitemid 38520528)
36. Haluzik M, Haluzikova D: The role of resistin in obesity-induced insulin resistance. Curr Opin Investig Drugs (2006) 7(4):306-311.
37. Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, Anderlová K, Müller-Ladner U, Pavelka K, Haluzík M: Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis (2007) 66(4):458-463. (Pubitemid 46580464)
38. Forsblad d'Elia H, Pullerits R, Carlsten H, Bokarewa M: Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (2008) 47(7):1082-1087.
39. Gómez-Ambrosi J, Frühbeck G: Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev (2005) 1(3):227-234.
40. Yamamoto Y, Fujiuchi S, Hiramatsu M, Nishigaki Y, Takeda A, Fujita Y, Yamazaki Y: Resistin is closely related to systemic inflammation in obstructive sleep apnea. Respiration (2008) 76(4):377-385.
41. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (2005) 436(7049):356-362. (Pubitemid 41065039)
42. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 354(24):2552-2563. (Pubitemid 43882351)
43. McTernan PG, Kumar S: Editorial: Retinol binding protein 4 and pathogenesis of diabetes. J Clin Endocrinol Metab (2007) 92(7):2430-2432. • Provides a critical discussion of the role of RBP4 and its role in diabetes.
44. Motani A, Wang Z, Conn M, Siegler K, Zhang Y, Liu Q, Johnstone S, Xu H, Thibault S, Wang Y, Fan P et al: Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem (2009) 284(12):7673-7680.
45. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E et al: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science (2005) 307(5708):426-430. (Pubitemid 40139988)
46. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, Gualillo O: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 65(9):1198-1201. (Pubitemid 44277396)
47. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol (2007) 178(3): 1748-1758. (Pubitemid 46154646)
48. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, Han JY, Han SY, Han KH, Kim HK, Cha DR: Visfatin: A new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol (2008) 295(5):F1485-F1494.
49. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ: The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med (2008) 12(4):1395-1403.
50. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M, Fasshauer M: Visfatin/PBEF/Nampt: Structure, regulation and potential function of a novel adipokine. Clin Sci (2008) 115(1):13-23. •• Comprehensive review of the adipokine visfatin.
51. Chavey C, Boucher J, Monthouël-Kartmann MN, Sage EH, Castan-Laurell I, Valet P, Tartare-Deckert S, Van Obberghen E: Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia. Obesity (2006) 14(11):1890-1897.
52. Takahashi M, Nagaretani H, Funahashi T, Nishizawa H, Maeda N, Kishida K, Kuriyama H, Shimomura I, Maeda K, Hotta K, Ouchi N et al: The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease. Obes Res (2001) 9(7):388-393. (Pubitemid 33603864)
53. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE: Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol (2003) 14(4):968-980. (Pubitemid 36359278)
54. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K: Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol (2007) 171(4):1104-1112. (Pubitemid 47582886)
55. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, Rumio C, Brekken RA, Chiodoni C, Colombo MP: Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res (2008) 68(21): 9050-9059.
56. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev (2008) 27(4):691-705.
57. Pan MR, Chang HC, Chuang LY, Hung WC: The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (2008) 233(4):456-462.
58. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Boggs J, Lacy JM, Zile MR: Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: Role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2009) 119(2):269-280.
59. Kos K, Wong S, Tan B, Gummesson A, Jernas M, Franck N, Kerrigan D, Nystrom FH, Carlsson LM, Randeva HS, Pinkney JH et al: Regulation of the fibrosis and angiogenesis promoter SPARC in human adipose tissue by weight change, leptin, insulin and glucose. Diabetes (2009) 58(8):1780-1788.
60. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE: Metabolic dysregulation and adipose tissue fibrosis: Role of collagen VI. Mol Cell Biol (2009) 29(6):1575-1591. • Presents a new concept of adipose tissue fibrosis in the pathogenesis of insulin resistance.
61. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ: A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell (2006) 125(3):577-591.
62. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K et al: Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA (2005) 102(30):10610-10615. (Pubitemid 41061602)
63. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Blüher M: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes (2008) 57(2):372-377.
64. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS: Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes (2008) 57(6): 1501-1507.
65. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem (2007) 282(38):28175-28188. (Pubitemid 47529521)
66. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, Iida K, Okimura Y, Kaji H, Kitazawa S, Kasuga M et al: Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett (2008) 582(5):573-578.
67. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D: Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology (2007) 148(10):4687-4694. (Pubitemid 47481514)
68. Cash JL, Hart R, Russ A, Dixon JP, Colledge WH, Doran J, Hendrick AG, Carlton MB, Greaves DR. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med (2008) 205(4):767-775. (Pubitemid 351549876)
69. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, Hunter M et al: Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat Med (2007) 13(11):1333-1340.
70. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C: Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology (2009) 150(4):1688-1696.
71. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL et al: Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA (2003) 100(6):3410-3415
72. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, Weedon H, Milliken ST, Tak PP, Smith MD, Breit SN: Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction. Arthritis Rheum (2007) 56(3):753-764. (Pubitemid 46399422)
73. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD: GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res (2006) 98(3):342-350.
74. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM: Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet (2002) 359(9324):2159-2163. (Pubitemid 34694024)
75. Seckl JR, Walker BR: Minireview: 11β-hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action. Endocrinology (2001) 142(4):1371-1376. (Pubitemid 32299662)
76. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol (Oxf) (1999) 50(1): 63-68. (Pubitemid 29079369)
77. Schnackenberg CG: 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome. Curr Opin Investig Drugs (2008) 9(3):295-300. • Reviews the background of 11βHSD inhibition and its therapeutic potential.
78. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess (2006) 10(42): 1-229. (Pubitemid 44910057)
79. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess (2007) 11(28):1-158. (Pubitemid 350079865)
80. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I et al: Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health Technol Assess (2006) 10(31):1-239. (Pubitemid 44659286)
81. Mima T, Nishimoto N: Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol (2009) 21(3):224-230.
82. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL: A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group. Cancer (2007) 110(6):1396-1403. (Pubitemid 47435614)
83. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ: Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr (2006) 84(6):1463-1472. (Pubitemid 44912832)